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e-mail address: Dr.sleiman@gmail.comSleiman Abou-LtaifAbstractPurpose: To assess the anatomical outcome of patients with exudative age-related macular degeneration resistant to ranibizumab
treated with aflibercept.
Method: Prospective, interventional, case series, where we treated a group of patients deemed resistant to Ranibizumab after
6 months of persistence of intra- or subretinal fluid despite continuous treatment.
Results: The study included 17 patients, 3 males and 14 females. The average males age was 85 (range 83–87), and that of females
was 79.64 (range 68–88).
At the start of the study, the central foveal thickness CFT average was 534.76 lm (range 252–999). At 1 month and after 1 injection
of Aflibercept, the CFT average was 324.82 lm (range 222–585). At 4 months and after 3 consecutive injections of Aflibercept the
CFT average was 294.76 lm (range 184–640). At 6 months the CFT average was 356 lm (range 206–609).
At the 5th visit only 8 out 17 (47%) patients required repeated injection either for persistent fluids or for recurrence. At the 6th and
final visit only 4 out of 17 (23.5%) needed repeated injections, of them only one was treated on the visit before and treatment was
given as very little response was observed from last injection, and all other 3 were not treated on the visit before.
Conclusion: Our results showed that aflibercept was able to dry the macula even in advanced case of wet AMD resistant to
Ranibizumab.
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Aflibercept (INN, USAN) is a biopharmaceutical drug
invented by Regeneron Pharmaceuticals, approved in the
United States and Europe for the treatment of wet macular
degeneration under the trade name Eylea. It is an inhibitor
of all types of vascular endothelial growth factor (VEGF) in
addition to the Placental growth factor (PGF).1
Aflibercept is a recombinant fusion protein consisting of
vascular endothelial growth factor (VEGF)-binding portions
from the extracellular domains of human VEGF receptors 1
and 2 that are fused to the Fc portion of the human IgG1
immunoglobulin.2
In the VIEW studies, two similarly designed, phase-3 stud-
ies (VEGF Trap-Eye: Investigation of Efficacy and Safety inWet AMD [VIEW 1, VIEW 2]) of neovascular age-related mac-
ular degeneration (AMD) compared monthly and every-2-
month dosing of intravitreal aflibercept injection (VEGF
Trap-Eye; Regeneron, Tarrytown, NY, and Bayer HealthCare,
Berlin, Germany) with monthly ranibizumab the most com-
monly used licensed Anti-VEGF treatment for exudative
age-related macular degeneration (AMD), and aflibercept
showed similar efficacy when used at fixed interval of
8 weeks. The studies were double-masked, multicentre,
parallel-group, active-controlled and randomized trials that
included 2419 Patients with active, submacular, choroidal
neovascularization (CNV) lesions.3
Recently same group4 released the data of 96 weeks of
follow-up of the VIEW studies, where patient following the
initial regimen for the first year was switched to follow ae:
al.com
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12 weeks interval. Results showed that proportions of eyes
maintaining best corrected visual acuity BCVA across treat-
ments were 94.4–96.1% at week 52 and 91.5–92.4% at week
96. Mean BCVA gains were 8.3–9.3 letters at week 52 and
6.6–7.9 letters at week 96. Proportions of eyes without retinal
fluid decreased from week 52 (60.3–72.4%) to week 96 (44.6–
54.4%), and more monthly treated (2q4) eyes were without
fluid at weeks 52 and 96 than monthly ranibizumab (Rq4)
eyes. The number of injections during weeks 52 through 96
was lower in the 2q4 and bimonthly treated (2q8) groups ver-
sus the Rq4 group.Method
In this prospective, interventional, study, we treated a
group of patients deemed resistant to Ranibizumab after
6 months of persistence of intra- or subretinal fluid (SRF)
despite continuous treatment. All patients were initially con-
sented to receive Ranibizumab and then re-consented for
Aflibercept. All patients had permanent foveal damage with
advanced submacular scarring. The main aim of the trial
was to access the number of patients with dry macula at
months 1, 4 and 6, and visual acuity change was a secondary
outcome.
Patients were treated with 3 monthly injections of afliber-
cept, with no treatment on the fourth visit, if required on the
fifth visit and if required and not being treated on the previ-
ous visit on the sixth visit.
Data were collected at every visit, including BCVA using
Log of the minimum angle of resolution (Log MAR) and opti-
cal coherence tomography OCT scan. Any ocular or non-
ocular adverse event was recorded.
The only inclusion criterion was the no response to ranibi-
zumab despite continuous treatment in the last 6 months
before switching. Exclusion criteria included continuous small
improvement to ranibizumab with residual IRF or SRF, good
response in case of recurrence. All patients attended their 6
visits, were seen, scanned, and treated by the same doctor.
All patients had no other macular abnormalities, including
epiretinal membrane, vitreomacular traction, taut posterior
hyaloid or any other retina-hyaloid interface abnormalities.
All patients had unilateral wet AMD disease, with only dry
macular changes in the fellow eye. And all patients were
pseudophakic in the treated eye except the female patient
aged 68 who was phakic.
All patients were given the choice of leaving the study at
every visit where they were confirming the willingness to con-
tinue to participate.Results
Our study included 17 patients, 3 males and 14 females.
The average males age was 85 (range 83–87), and that of
females was 79.64 (range 68–88) (Photo 1).
The time since diagnosis of exudative AMD was quite vari-
able ranging from 18 to 67 months. Patients received treat-
ment very frequently to the day of starting our study with
an average number of injections of 16.47 (range of 8–29) with
average number of visits of 25.29 (range 14–39) over an aver-
age period of 37.64 months (range of 18–67).At the start of the study, the central foveal thickness (CFT)
average was 534.76 lm (range 252–999). At 1 month and
after 1 injection of Aflibercept, the CFT average was
324.82 lm (range 222–585). At 4 months and after 3 consec-
utive injection of Aflibercept the CFT average was 294.76 lm
(range 184–640). At 6 months the CFT average was 356 lm
(range 206–609).
At the 5th visit only 8 out 17 (47%) patients required
repeated injection either for persistent fluids or for recur-
rence. At the 6th and final visit only 4 out of 17 (23.5%)
needed repeated injections, of them only one was treated
on the visit before and treatment was given as very little
response was observed from last injection, and all other 3
were not treated on the visit before.
Immediate response was observed in all patients after first
injection of Aflibercept (Graph 1).
Best corrected visual acuity BCVA, at the beginning of the
study had an average of 0.998, and at month 1 the average
was 1.01, at month 4 and after 3 consecutive injections of
Aflibercept the average of BCVA was 0.952 and at month 6
it was 0.933 (Graph 2).
The anatomical improvement did not correlate with func-
tional improvement in all patients, a fact that we anticipated
and all patients were cautioned before entering the study. All
patients were back to PRN regimen after the sixth visit
(Graph 3).
No cases of endophthalmitis ocular or systemic side
effects were observed.Discussion
In 2007, ranibizumab was licensed to treat the exudative
form of AMD, following 2 pivotal trials, Anchor and Marina.
Many regimens were advocated thereafter, namely monthly
treatment similar to the trials, PRN regimens, treat and
extend and even 3 monthly.
In the Trials of Ranibizumab in the Treatment of Neovascu-
lar AMD (MARINA) and Anti-VEGF Antibody for the Treat-
ment of Predominantly Classic Choroidal Neovascularization
in AMD (ANCHOR), 95% of ranibizumab-treated patients
maintained visual acuity compared to 62% of sham or photo-
dynamic therapy (PDT) groups (p < 0.01) at 1 year. Further-
more, up to 40% demonstrated an improvement in vision of
at least three lines.5
It is still unknown why more than half of patients do not
improve after anti-VEGF therapy and about 10% of patients
do not respond at all to treatment. Tachyphylaxis or loss of
drug effectiveness after repetitive injections of ranibizumab
was recently recognized. Genetic factors are another impor-
tant parameter that should be considered.
Tranos et al. conducted a review of the literature for the
possible causes of failure after treatment with anti-VEGF
agents.6 They conducted a comprehensive search of the liter-
ature published until 2012 to identify studies evaluating the
effects of anti-VEGF therapeutic agents in the management
of AMD. These included randomized controlled studies,
prospective and retrospective case-control studies, and case
series. Studies with other clinical subtypes of AMD were not
excluded. English and non-English language articles with
abstracts translated into English were retrieved too. These
searches were supplemented by manually searching the
reference lists of all major review articles.
Photo 1. This collection of patients before and after 3 injections of aflibercept illustrates clearly the major anatomical improvement is almost all patients.
Picture on the left or on the top in coupled pictures in before, picture on the right or the bottom is the after treatment.
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anti-VEGF may be due in nearly 50% of cases to misdiagnosis
of AMD, such as polypoidal choroidal vasculopathy (PCV)that accounts for the majority of the underlying pathology.
Tachyphylaxis also appeared to play a significant role and
they believed that a small number of AMD patients may be
Graph 1. This graph shows the visual acuity decline in all patients from day of diagnosis to the day of switch to aflibercept. It shows clear stead
deterioration of vision in all patients.
Graph 2. This graph shows the central foveal thickness in all patients during the 6 months of treatment. It shows immediate response to first injection in
all patients. Final thickness is better than the initial in all patients.
230 S. Abou-Ltaifgenetically predisposed to show resistance to anti-VEGF
treatment.
In 2011, Manoj 7 published a retrospective study between
January 2007 and December 2008 to evaluate eyes withAMD that responded poorly to anti-VEGF therapy and to
investigate reasons for treatment failure. In 24 eyes (46.2%)
of the patients with poor response to treatment, he identified
cases of PCV (19 eyes), retinal angiomatous proliferation
Graph 3. This graph illustrates the visual acuity changes during the study. It confirms the stable visual acuity with very mild gain in some patients but no
deterioration.
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excluding the misdiagnosed cases, 14 eyes (26.9%) were
identified, which were nonresponders and eleven eyes
(22.2%) which fulfilled the criteria for diagnosing Tachyphy-
laxis. Six eyes (11.5%) developed complications such as reti-
nal pigment epithelium (RPE) tear, scarring, RPE atrophy,
and eventually poor visual outcome.
Immunization against Ranibizumab was recently identified
in 17% of patients treated with Ranibizumab, using ELISA, in
a study conducted by Leveziel et al.8 This study showed that
no immunization was detected among naïve patients and it
increased with the number of injections. For patients with
10 or fewer previous IVTs, immunization against Ranibizumab
was detected in 4/36 patients (11.1%) whereas immunization
was observed in 10/46 patients (21.7%) with more intravitreal
injections (IVTs).
In an approach to try to understand the pathology of resis-
tant cases, Shin JY et al.9 described OCT characteristics of
wet AMD patients refractory to IVTs (Ranibizumab, Beva-
cizumab) and their responses to alternative anti-VEGF agents
or photodynamic therapy (PDT).
In his retrospective review of 267 neovascular AMD
patients treated with intravitreal anti-VEGF injections, 20
patients (7.5%) were refractory to anti-VEGF injections (sta-
tionary or increased retinal exudation despite three or more
monthly injections). He grouped them into either the exten-
sive intraretinal fluid group (9 patients) or the subretinal fluid
only group (11 patients) according to OCT findings. In the IRF
group, response rates to subsequent treatment were 0%
(0/7) for Bevacizumab, 50% (3/6) for Ranibizumab and 50%
(3/6) for PDT ± anti-VEGF. Three out of four Bevacizumab-
refractory patients showed response to Ranibizumab as a
secondary treatment. In the SRF group, response rates were
lower with 0% (0/7) for Bevacizumab, 22.2% (2/9) for Ranibi-zumab and 28.6% (2/7) for PDT ± anti-VEGF. One out of four
Bevacizumab-refractory patients responded to Ranibizumab.
In anti-VEGF-refractory neovascular AMD, patients with
extensive IRF refractory to Bevacizumab can be responsive
to Ranibizumab while patients with SRF may be refractory
to both, suggesting a different pathophysiology and intraoc-
ular pharmacokinetics.
With the release of Aflibercept with 100 times affinity to
VEGF10, many authors introduced this new drug in cases with
no response to Ranibizumab, with variable results.
In a retrospective review at Ophthalmic Consultants of
Boston, Cho et al.11 evaluated the anatomical and visual
effect of intravitreal Aflibercept 2.0 mg in cases of exudative
age-related macular degeneration (AMD) with persistent
fluid on optical coherence tomography (OCT) despite regular
Ranibizumab 0.5 mg and/or Bevacizumab 1.25 mg treatment
at 1 and 6 months.
They included a total of 353 eyes with exudative AMD that
were switched to Aflibercept during the study period. Of
these, 28 eyes in 28 patients had persistent fluid after an
average of 20 regular Ranibizumab/Bevacizumab injections
(range 7–37). At 1 month, 89% (25 eyes) showed anatomical
improvement and 18% (five eyes) were dry after a single
Aflibercept injection. Central subfoveal thickness improved
from 295 to 272 lm (p < 0.001) after one Aflibercept injec-
tion. After an average of 4.4 Aflibercept injections (range
3–6) over 6 months, the central subfoveal thickness remained
improved (274 lm, p = 0.008); 64% (18 eyes) showed anato-
mical improvement and a quarter of eyes (25%, seven eyes)
were dry.
Visual acuity did not improve at 1 month (Log MAR 0.54,
p = 0.64) or 6 months (Log MAR 0.57, p = 0.49). Despite no
improvement in visual acuity, a significant proportion of cases
responded anatomically to Aflibercept 2.0 mg.
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ing for Ranibizumab/ Bevacizumab resistant cases and identi-
fied 36 eyes from 31 patients.
There were 13 male and 18 female patients. The number
of prior injections with either Bevacizumab or Ranibizumab
ranged from 6 to 74. After 3 monthly injections of Afliber-
cept, there was a reduction in either subretinal or intraretinal
fluid in 18 of 36 (50.0%) of the treated eyes; the amount of
fluid remained stable in 15 eyes (41.7%) and worsened in 3
eyes (8.3%). A significant average decrease was observed
for the central macular thickness after 3 injections of 65 lm,
with no significant change in visual acuity.
In addition to Aflibercept, the 2 mg dose of Ranibizumab
was the subject of a trial in patients recalcitrant to ranibizu-
mab 0.5 mg dose.13 This Phase I-II trial of 88 patients with
recalcitrant neovascular AMD treated as needed for every 4
(cohort A) or 6 weeks (cohort B) following three monthly
doses. 79 patients completed the 12-month endpoint and
were given 11.6 (cohort A) and 8.6 (cohort B) mean treat-
ments. Mean best corrected visual acuity gains of 4.1 letters
following three monthly doses were sustained for 12 months
for both cohorts. Anatomical improvements were sustained
for 12 months for cohort A, but not for cohort B; cohort B
demonstrated a gradual increase in mean central retinal
thickness (p = 0.03).
The interesting fact in this trial is that visual and anatomical
gains achieved with 2.0 mg Ranibizumab in recalcitrant neo-
vascular AMD were sustained for 1 year only with monthly
treatment. In comparison, anatomical gains were reduced
with less than monthly treatment.
Conclusion
In our study, all patients previously non-responding to
Ranibizumab had immediate response to aflibercept shown
as reduction in macular thickness mainly from the first
injection.
The strength of this study comes from the prospective
design, the absence of selection bias of patients as all
patients with no response to ranibizumab were included
regardless of their visual acuity, macular status or the amount
of fluid in the macula.
The weakness of this study comes from the small number
of patients treated, the short follow-up time and the fact that
no Indocyanine green angiography (ICG) was performed to
rule out polypoidal lesions although one case was suspicious
of PCV, however we had a considerable anatomical improve-
ment, although not complete, in that case.
Aflibercept was able to dry all maculaes even in very
advanced cases deemed untreatable and is recommendedas a treatment option in cases of no-response to
ranibizumab.
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